Conductive stimuli-responsive coordination network linked with bismuth
US-2024199664-A1 · Jun 20, 2024 · US
US10501487B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10501487-B2 |
| Application number | US-201615576531-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 26, 2016 |
| Priority date | May 26, 2015 |
| Publication date | Dec 10, 2019 |
| Grant date | Dec 10, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided herein are organobismuth (III) phosphinate complexes, which comprise a phosphinate group and an aromatic carbocyclyl or aromatic heterocyclyl group. The complexes find use as antibacterial agents, and accordingly also provided herein are products, devices, compositions and materials comprising the complexes, for example medical products such as wound dressings and bandages.
Opening claim text (preview).
The invention claimed is: 1. An organobismuth (III) phosphinate complex having a structure comprising formula (a): wherein R 1 is a phosphinate group; R 2 is an aromatic carbocyclyl or aromatic heterocyclyl group; and R 3 is a phosphinate group, an aromatic carbocyclyl or aromatic heterocyclyl group, or a ligand; and wherein the complex is not 2. The complex of claim 1 , wherein R 3 is a phosphinate group, or an aromatic carbocyclyl or aromatic heterocyclyl group. 3. The complex of claim 2 , wherein R 3 is a phosphinate group. 4. The complex of claim 1 , wherein the phosphinate group has the formula (b) and each R a is independently selected from the group consisting of hydrogen, optionally substituted C 1-10 alkyl, optionally substituted C 2-10 alkenyl, optionally substituted C 2-10 alkynyl, optionally substituted C 3-10 carbocyclyl and optionally substituted C 3-10 heterocyclyl. 5. The complex of claim 4 , wherein the complex has the formula (c) 6. The complex of claim 5 , wherein each R a is hydrogen. 7. The complex of claim 5 , wherein each R a is unsubstituted C 1-6 alkyl. 8. The complex of claim 5 , wherein each R a is C 6-10 aromatic carbocyclyl or C 6-10 aromatic heterocyclyl, said aromatic carbocyclyl or aromatic heterocyclyl being unsubstituted or substituted with up to 3 substituents selected from the group consisting of halogen, —CN, —NO 2 , —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl and —OC 1-6 alkyl. 9. The complex of claim 5 , wherein R a is selected from the group consisting of hydrogen, C 1-6 alkyl, C 6-10 aromatic carbocyclyl or C 5-10 aromatic heterocyclyl, said aromatic carbocyclyl or aromatic heterocyclyl being unsubstituted or substituted with up to 3 substituents selected from the group consisting of halogen, —CN, —NO 2 , —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl and —OC 1-6 alkyl; and R 2 is C 6-10 aromatic carbocyclyl or C 5-10 aromatic heterocyclyl, said aromatic carbocyclyl or aromatic heterocyclyl being unsubstituted or substituted with up to 3 substituents each independently selected from the group consisting of halogen, —CN, —NO 2 , C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl and —OC 1-6 alkyl. 10. The complex of claim 1 , wherein R 2 is C 6-10 aromatic carbocyclyl or C 5-10 aromatic heterocyclyl, said aromatic carbocyclyl or aromatic heterocyclyl being unsubstituted or substituted with up to 3 substituents each independently selected from the group consisting of halogen, —CN, —NO 2 , C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl and OC 1-6 alkyl. 11. The complex of claim 10 , wherein R 2 is phenyl which is unsubstituted or substituted with up to 3 substituents each independently selected from the group consisting of halogen, —CN, —NO 2 , C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl and OC 1-6 alkyl. 12. The complex of claim 1 , wherein the complex is selected from the group consisting of: 13. The complex of claim 1 , wherein the complex is: 14. A product, device, material, or composition comprising a complex of claim 1 . 15. The product, device, material, or composition of claim 14 , wherein the product, device, material or composition comprises an antibacterial surface coating comprising the complex. 16. The composition of claim 14 , wherein the composition is a polymerisable and/or curable composition. 17. The product, device, material, or composition of claim 15 , wherein the product, device, material, or composition is a wound dressing, a suture, a surgical implement, or a medical implant. 18. The product, device, composition, or material of claim 14 , wherein the product, device, material, or composition is a medical adhesive, a bone cement, a dental adhesive or a dental filler composition. 19. The product, device, material, or composition of claim 14 , wherein the product, device, material, or composition is for use in building construction, renovation, and/or maintenance and wherein the product, device, material, or composition is a coating, sealant, cement, concrete, grout, mortar, or stucco composition. 20. The product, device, material, or composition of claim 14 , wherein the product, device, material, or composition comprises antibacterial packaging comprising the complex. 21. The product, device, material, or composition of claim 14 , wherein the product, device, material, or composition is a cellulosic material.
Antibacterial agents · CPC title
Medicaments · CPC title
Phosphorus; Compounds thereof · CPC title
Bismuth; Compounds thereof · CPC title
Medicaments; Biocides · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.